NX Development Corp.'s Unattributed - II Round

NX Development Corp. raised a round of funding on May 27, 2016.

NX PharmaGen's business model is to acquire, develop, and monetize mature clinical-stage breakthrough technologies. The company's lead program is a disruptive diagnostic technology, termed the NeXosom…

Articles about NX Development Corp.'s Unattributed - II Round: